Advanced therapies: marketing authorisation

  • Email
  • Help

The European Medicines Agency (EMA) is responsible for the scientific evaluation of marketing authorisation applications for all advanced therapy medicinal products (ATMPs) in the European Economic Area, as they fall under the mandatory scope of the centralised procedure. 

Companies can receive a confirmation from EMA that a medicine they are developing meets the scientific criteria for defining an ATMP before submitting a marketing authorisation application.

In this section


How useful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Related content

Contact point